Friends of Cancer Research Virtual Meeting
Enhancing Diversity in Clinical Trials: Implementation of Diversity Plans
Thursday, February 15, 2024
12:00PM – 1:30PM ET
Thank you to all that attended!
Click HERE to Watch the Meeting.
Click HERE to read the meeting discussion document.
Friends of Cancer Research (Friends) is proud to announce a new virtual meeting, Enhancing Diversity in Clinical Trials: Implementation of Diversity Plans.
The U.S. Food and Drug Administration’s (FDA) draft guidance and the Food and Drug Omnibus Reform Act (FDORA) emphasize the importance of establishing diversity plans to ensure that clinical trials are more inclusive and investigational treatments are equally safe and effective across all populations. Discussions at this meeting will highlight insights and recommendations regarding the implementation of diversity plans, the use of various data sources, and current practices to establish enrollment goals for racial and ethnic diversity in clinical trials.
Agenda
12:00PM – Welcoming Remarks
12:03PM – Opening Keynotes
- Rep. Anna Eshoo (D-CA)
- Namandjé N. Bumpus, Principal Deputy Commissioner, U.S. FDA
12:15PM – Session 1: Data-Driven Approaches for Establishing Diversity Enrollment Targets
- Riha Vaidya, Fred Hutchinson Cancer Center — Moderator
- Xoli Belgrave, Parexel
- Henry Bennett, Novartis
- ‘Lola Fashoyin-Aje, U.S. FDA
- Anne-Michelle Noone, National Cancer Institute
- Cleo A. Ryals, Flatiron Health
12:50PM – Session 2: Operational Approaches and Insights for More Inclusive Clinical Trials
- Anjee Davis, Fight Colorectal Cancer — Moderator
- Lucy Gansauer, SWOG Cancer Research Network & Spartanburg Regional Healthcare
- Edward Kim, City of Hope Orange County
- Kristi Mitchell, Atlas Clarity LLC & Health Equity Outcomes (HEO)
- Nicole Richie, Genentech, Inc.
1:25PM – Closing Remarks
1:30PM – Meeting Conclusion
